---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-025539"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:25:02.537468+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vaxart Q2 net loss narrows to $16.5M; BARDA award up to $453M for COVID Phase 2b

## Summary
- Net loss per share $0.09 vs $0.16 YoY; revenue $6.4M (from $1.4M) on BARDA contract.
- Cash and investments $62.6M at June 30; received ~$64.7M BARDA payment post-quarter.
- BARDA Project NextGen award up to $453M to support 10,000-subject Phase 2b COVID trial vs mRNA comparator.
- Enrollment for Phase 2b expected in H2 2024 pending FDA alignment; cash runway into 2026.
- Norovirus vaccine: in discussions with FDA on correlates of protection; evaluating Phase 2b/challenge study.

## SEC filing metadata
- accession: 0001437749-24-025539
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774924025539/0001437749-24-025539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774924025539/vxrt20240529_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-025539
- JSON: https://secwatch.observer/filing/0001437749-24-025539.json
- Plain text: https://secwatch.observer/filing/0001437749-24-025539.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.